US4472382A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment method
Assignee: Aventis Pharma SA
•
Filing: 1983-02-23
•
Granted: 1984-09-18
•
Expires: 2003-02-23
Abstract
Abstract A novel method of treating prostate adenocarcinoma, prostate benign hypertrophia, endometriosis, dysmenorrhea, hirsuitism, hormono-dependent mammary tumors, treatment and prevention of precocious puberty, induction of a retardation of the appearance of puberty and treatment of acne of mammals comprising administering to warm-blooded animals an effective amount of a peptide of the formula p Glu--His--Trp--Ser--Tyr--X--Y--Arg--Pro--Z (I) wherein (a) Z is Gly--NH 2 , Y is Leu and X is Gly, (b) Z is Gly--NH 2 , Y is Leu, X is DN Leu, DN Val, D Abu (α-aminobutyric acid), D Phe, D Ser, D Thr, D Met, D Pgl, D Lys, Leu, Ile, Nle, Val, N Val, Met, Phe, D Leu, D Arg, D Ser (tbu), D Thr (tbu), D Cys (tbu), D Asp (O tbu), D Glu (Otbu), D Orn (boc), D Lys (boc), D Trp, Trp, 2-methyl Ala, D Tyr, D Met, ε-lauryl -D Lys, ε-dextran-D Lys, (c) Z is NH-cyclopropyl-or NH--Alk wherein Alk is alkyl of 1 to 3 carbon atoms, Y is Leu and X is D Ser (tbu), D Thr (tbu), D Asp (Otbu), D Glu (Otbu), D Orn (boc), D Lys (boc), (d) Z is --NH--CH 3 , --NH--CH 2 --CH 3 , NH--CH 2 --CH 2 --CH 3 , --NH--CH 2 --CH 2 --OH, ##STR1## Y is Leu and X is Gly, (e) Z is --NH--CH 2 --CH 3 , Y is Leu and X is D Trp, D Leu, D Ala, D Ser (tbu), D Tyr, D Lys, Ala, (f) Z is Gly--NH 2 or --NH--CH 2 --CH 3 , Y is NαMe Leu and X is Gly, (g) Z is --NH--cyclopropyl, Y is Leu and X is D Leu or (h) Z is Gly--NH 2 , --NH--cyclopropyl or --NHAlk' where Alk' is alkyl of 1 to 3 carbon atoms, Y is Ser (but), Cys (but), Asp (Obut), Glu (Obut), Orn (boc), Lys (boc) and X is Gly.
Inventors
- 👤 Fernand Labrie
- 👤 Jean-Pierre Raynaud
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 16:58
CPC Classifications
C; C07; C07K; C07K7/00; C07K7/04; C07K7/23; A; A61; A61P; A61P13/00; A61P13/02; A61P15/00; A61P35/00; A61P5/00; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/13
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
303 words
A method for the treatment of prostate adenocarcinoma and prostate benign hypertrophaia comprising administering to male warm-blooded animals an effective amount of an association of an antiandrogen and a peptide of the formula p Glu--His--Trp--Ser--Tyr--X--Y--Arg--Pro--Z (I) wherein (a) Z is Gly--NH 2 , Y is Leu and X is Gly, (b) Z is Gly--NH 2 , Y is Leu, X is DN Leu, DN Val, D Abu (α-aminobutyric acid), D Phe, D Ser, D Thr, D Met, D Pgl, D Lys, Leu, Ile, Nle, Val, N Val, Met, Phe, D Leu, D Arg, D Ser (tbu), D Thr(tbu), D Cys, (tbu), D Asp (Otbu), D Glu (Otbu), D Orn (boc), D Lys (boc), D Trp, Trp, 2-methyl Ala, D Tyr, D Met, ε-lauryl-D Lys, ε-dextran-D Lys, (c) Z is NH-cyclopropyl or --NH-Alk wherein Alk is alkyl of 1 to 3 carbon atoms, Y is Leu and X is D Ser (tbu), D Thr (tbu), D Asp (Otbu), D Glu (Otbu), D Orn (boc), D Lys, (boc), (d) Z is --NH--CH 3 , --NH--CH 2 --CH 3 , NH--CH 2 --CH 2 --CH 3 , --NH--CH 2 --CH 2 --OH, ##STR3## Y is Leu and X is Gly, (e) Z is --NH--CH 2 --CH 3 , Y is Leu and X is D Trp, D Leu, D Ala, D Ser (tbu), D Tyr, D Lys, Ala, (f) Z is Gly--NH 2 or --NH--CH 2 --CH 3 , Y is NαMe Leu and X is Gly, (g) Z is --NH-cyclopropyl, Y is Leu and X is D Leu or (h) Z is Gly--NH 2 , --NH-cyclopropyl or --NHAlk' where Alk' is alkyl of 1 to 3 carbon atoms, Y is Ser (but), Cys (but), Asp (Obut), Glu (Obut), Orn (boc), Lys (boc) and X is Gly sufficient to treat prostate adenocarcinoma and prostate benign hypertrophia.
Claim 2
Independent Claim
303 words
A method for the treatment of prostate adenocarcinoma and prostate benign hypertrophaia comprising administering to male warm-blooded animals an effective amount of an association of an antiandrogen and a peptide of the formula p Glu--His--Trp--Ser--Tyr--X--Y--Arg--Pro--Z (I) wherein (a) Z is Gly--NH 2 , Y is Leu and X is Gly, (b) Z is Gly--NH 2 , Y is Leu, X is DN Leu, DN Val, D Abu (α-aminobutyric acid), D Phe, D Ser, D Thr, D Met, D Pgl, D Lys, Leu, Ile, Nle, Val, N Val, Met, Phe, D Leu, D Arg, D Ser (tbu), D Thr(tbu), D Cys, (tbu), D Asp (Otbu), D Glu (Otbu), D Orn (boc), D Lys (boc), D Trp, Trp, 2-methyl Ala, D Tyr, D Met, ε-lauryl-D Lys, ε-dextran-D Lys, (c) Z is NH-cyclopropyl or --NH-Alk wherein Alk is alkyl of 1 to 3 carbon atoms, Y is Leu and X is D Ser (tbu), D Thr (tbu), D Asp (Otbu), D Glu (Otbu), D Orn (boc), D Lys, (boc), (d) Z is --NH--CH 3 , --NH--CH 2 --CH 3 , NH--CH 2 --CH 2 --CH 3 , --NH--CH 2 --CH 2 --OH, ##STR3## Y is Leu and X is Gly, (e) Z is --NH--CH 2 --CH 3 , Y is Leu and X is D Trp, D Leu, D Ala, D Ser (tbu), D Tyr, D Lys, Ala, (f) Z is Gly--NH 2 or --NH--CH 2 --CH 3 , Y is NαMe Leu and X is Gly, (g) Z is --NH-cyclopropyl, Y is Leu and X is D Leu or (h) Z is Gly--NH 2 , --NH-cyclopropyl or --NHAlk' where Alk' is alkyl of 1 to 3 carbon atoms, Y is Ser (but), Cys (but), Asp (Obut), Glu (Obut), Orn (boc), Lys (boc) and X is Gly sufficient to treat prostate adenocarcinoma and prostate benign hypertrophia.
Claim 3
Dependent Claim
11 words
The method of claim 1 wherein the antiandrogen is 5,5-dimethyl-3-[4-nitro-3-trifluoromethyl-phenyl]-2,4-imidazolidine dione.
Claim 4
Dependent Claim
10 words
The method of claim 1 wherein the antiandrogen is 2-methyl-N-[4-nitro-3-trifluoromethyl-phenyl]-propanamide.
Claim 5
Dependent Claim
33 words
The method of claim 1 wherein Z is --NH--CH 2 --CH 3 , Y is Leu and X is D Trp, D Leu, D Ala, D Ser (Tbu), D Tyr, D Lys, Ala.
Claim 6
Dependent Claim
23 words
The method of claim 1 wherein the peptide is [D Ser (Tbu) 6 , of des Gly NH 2 10 ] LH--RH ethylamide.
Claim 7
Dependent Claim
17 words
The method of claim 1 wherein the daily dose of the peptide is 10 to 100,000 μg.
Claim 8
Dependent Claim
20 words
The method of claim 1 wherein the peptide is administered intranasally at a daily dose of 100 to 100,000 μg.
Claim 9
Dependent Claim
20 words
The method of claim 1 wherein the peptide is administered parenterally at a daily dose of 10 to 10,000 μg.
Claim 10
Dependent Claim
35 words
The method of claim 1 wherein the peptide is [D Ser (Tbu) 6 , des Gly NH 2 10 ] LH--RH ethylamide and is administered parenterally at a daily dose of 10 to 200 μg.
Claim 11
Dependent Claim
35 words
The method of claim 1 wherein the peptide is [D Ser (Tbu) 6 , des Gly NH 2 10 ] LH--RH ethylamide and is administered intranasally at a daily dose of 100 to 2000 μg.
Claim 12
Dependent Claim
17 words
The method of claim 9 wherein the peptide is administered once or twice a day each day.
Claim 13
Dependent Claim
17 words
The method of claim 10 wherein the peptide is administered once or twice a day each day.
Claim 14
Dependent Claim
20 words
The method of claim 9 wherein the peptide is administered once or twice a day with intervals of several days.
Claim 15
Dependent Claim
20 words
The method of claim 10 wherein the peptide is administered once or twice a day with intervals of several days.
Claim 16
Dependent Claim
20 words
The method of claim 1 wherein the daily dose of the antiandrogen is 10 mg to 1 g per day.
Claim 17
Dependent Claim
20 words
The method of claim 6 wherein the daily dose of the antiandrogen is 10 mg to 1 g per day.
Claim 18
Independent Claim
43 words
A method for the treatment of prostate adenocarcenoma and prostate benign hypertrophial comprising administering to male humans an effective amount of an association of [D-Ser (TBu) 6 ,des-Gly-NH 2 10 ]-LH--RH ethylamide and 5,5-dimethyl-3-[4-nitro-3-trifluoromethyl-phenyl]-2,4-imidazolidine-dione sufficient to treat prostate adenocarcenoma and prostate benign hypertrophia.
Claim 19
Independent Claim
43 words
A method for the treatment of prostate adenocarcenoma and prostate benign hypertrophial comprising administering to male humans an effective amount of an association of [D-Ser (TBu) 6 ,des-Gly-NH 2 10 ]-LH--RH ethylamide and 5,5-dimethyl-3-[4-nitro-3-trifluoromethyl-phenyl]-2,4-imidazolidine-dione sufficient to treat prostate adenocarcenoma and prostate benign hypertrophia.
Claim 20
Dependent Claim
34 words
The method of claim 17 wherein the daily dose of 5,5-dimethyl-3-[4-nitro-3-trifluoromethyl-phenyl]-2,4-imidazolidine-dione is 10 mg to 1 g per day and the daily dose of the said peptide is 10 to 100,000 mg per day.
References Cited (Backward Citations)
US3835108A
Cited
US3880825A
Cited
US4002738A
Cited
US4005194A
Cited
US4071622A
Cited
US4234571A
Cited
US4244946A
Cited
FR2465486A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-09-18 | 1988-03-19 | 1988-09-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-09-18 | 1992-03-19 | 1992-09-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-09-18 | 1996-03-19 | 1996-09-18 | $7700.00 | Window Closed / Lapsed |